Existing and emerging endocrine therapies for breast cancer

Cancer Nursing

Volumn 25, Issue 2 SUPPL., 2002, Pages

  Dow, Karen Hassey ^a  

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Aromatase inhibitors; Endocrine therapy; Estrogen receptor downregulators; Fulvestrant; Megestrol; Metastatic breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL; TAMOXIFEN;

ADVANCED CANCER; ARTHRALGIA; ARTHROPATHY; BREAST CANCER; CANCER SURVIVAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VAGINITIS;

EID: 0036206491     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002820-200203001-00002     Document Type: Review

References (43)

1. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database
2. The value of estrogen and progesterone receptors in the treatment of breast cancer
3. Inflammatory breast cancer: A review
4. Endocrine treatment of breast cancer
5. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
6. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
7. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
8. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
9. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
10. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
11. Anastrozole: A new addition to the armamentarium against advanced breast cancer
12. Breast cancer
13. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
14. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: Update on clinical trials since 1995
15. Selective estrogen-receptor modulators in 2001
16. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
17. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
18. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen
19. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
20. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
21. Endometrial lesions after tamoxifen therapy in breast cancer women
22. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer
23. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: A quantitative review of published randomized clinical trials
24. A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer
25. Anti-aromatase agents in malignant diseases of aging
26. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
27. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
28. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
29. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal women: Combined analyses from two identically designed multicenter trials
30. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
31. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
32. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results from a phase III study of the international letrozole breast cancer group
33. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): Results of a randomized phase II trial
34. A potent specific pure antiestrogen with clinical potential
35. ICI 182,780, a new antioestrogen with clinical potential
36. Novel steroidal pure antiestrogens
37. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
38. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
39. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
40. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
41. ICI 182,780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain
42. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
43. ICI 182,780 (Faslodex™) is at least as effective as anatrozole (Arimidex™) in postmenopausal women with advanced breast cancer progressing on prior endocrine treatment